Search Results
Oct 15, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
(RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
Oct 13, 2025, 10:57 ET U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement
More news about: AbbVie
Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment
More news about: AbbVie
Oct 09, 2025, 08:00 ET SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
IRVINE, Calif., Oct. 9, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the rollout of SkinMedica®'s reimagined packaging—a modernized look that elevates the consumer experience while advancing
More news about: AbbVie
Oct 09, 2025, 07:05 ET REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-vec) for the treatment of diabetic retinopathy (DR) at the American Academy of Ophthalmology 2025 Annual Meeting. Sura-vec, developed in collaboration
More news about: REGENXBIO Inc.
Oct 06, 2025, 09:00 ET AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
NORTH CHICAGO, Ill., Oct. 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to
More news about: AbbVie
Oct 06, 2025, 07:05 ET REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
announced the completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal studies evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet age-related macular degeneration (wet AMD) using subretinal delivery. "Completing enrollment in this large, global
More news about: REGENXBIO Inc.
Oct 02, 2025, 08:00 ET Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease
earlier.3 About ABBV-CLS-628ABBV-CLS-628, an investigational human monoclonal antibody designed to inhibit PAPP-A activity, is being evaluated for the treatment of ADPKD. ABBV-CLS-628 has completed a Phase 1 study in healthy volunteers (ACTRN12622001550796)
More news about: Calico
Oct 02, 2025, 08:00 ET AbbVie to Host Third-Quarter 2025 Earnings Conference Call
NORTH CHICAGO, Ill., Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the
More news about: AbbVie
Oct 01, 2025, 08:00 ET Natrelle® Awarded Supplier Agreement from Vizient
IRVINE, Calif., Oct. 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that Natrelle® has been named a supplier by Vizient, Inc., the nation's largest provider-driven healthcare performance improvement
More news about: AbbVie
Sep 30, 2025, 15:00 ET AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center
More news about: AbbVie
Sep 30, 2025, 08:00 ET AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational
More news about: AbbVie
Sep 29, 2025, 12:00 ET AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is
More news about: AbbVie
Sep 29, 2025, 09:00 ET AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced
More news about: AbbVie
Sep 29, 2025, 07:05 ET REGENXBIO Announces Presentation at the World Muscle Society
RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been
More news about: REGENXBIO Inc.
Sep 26, 2025, 08:45 ET AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
NORTH CHICAGO, Ill., Sept. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine
More news about: AbbVie
Sep 25, 2025, 05:00 ET Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
Calif., Sept. 25, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic
More news about: AbbVie
Sep 23, 2025, 05:00 ET Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
Calif., Sept. 23, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additional markets this year bringing the total to 57 globally in 2025. This
More news about: AbbVie